Rasio cepet Addex Therapeutics (ADXN)

The historical price action of Addex Therapeutics (ADXN) demonstrates the development of a business that relies on strategic alliances with global industry leaders to combat Parkinson's pathologies. The current metric stands at 0.79, while the company focuses on the internal advancement of its developments and targeted licensing of rights. Patents for brain degeneration treatments create a foundation of stability, guaranteeing perpetual demand and a constant cash flow.

Addex Therapeutics (ADXN) develops unique drugs for the therapy of neurological disorders based on allosteric modulation. This activity requires significant expenditures, which are weighed against the volume of cash and accounts receivable minus inventory. The ratio determines the company's ability to instantaneously settle short-term debts without liquidating complex assets. By analyzing the critical liquidity trend, an investor assesses the biotech's financial stability until it achieves pricing power in the market.